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Summary
There is an urgent need for pre-clinical and clinical
biomarkers predictive of vaccine immunogenicity,
efficacy and safety to reduce the risks and costs
associated with vaccine development. Results emerg-
ing from immunoproﬁling studies in non-human pri-
mates and humans demonstrate clearly that (i) type
and duration of immune memory are largely deter-
mined by the magnitude and complexity of the innate
immune signals and (ii) genetic signatures highly pre-
dictive of B-cell and T-cell responses can be identiﬁed
for speciﬁc vaccines. For vaccines with similar com-
position, e.g. live attenuated viral vaccines, these sig-
natures share common patterns. Signatures
predictive of vaccine efficacy have been identiﬁed in
a few experimental challenge studies. This review
aims to give an overview of the current literature on
immunoproﬁling studies in humans and also pre-
sents some of our own data on proﬁling of licensed
and experimental vaccines in non-human primates.
Introduction
Vaccination remains the most cost-effective measure to
prevent infectious diseases, and many are readily pre-
ventable through induction of protective immunity espe-
cially functionally active antibodies, e.g. diseases caused
by bacterial toxins, several viruses and some encapsu-
lated bacteria (Plotkin, 2010). For many other important
pathogens, such as P. falciparum, M. tuberculosis,
Human Immunodeﬁciency Virus and S. aureus, however,
correlates of protection are either not known, or it is
unclear how to best induce potent polyfunctional immune
responses that are broad and long-lived. These are major
obstacles to rational vaccine design that have resulted in
numerous failed clinical trials and are major contributors
to the increasing costs of vaccine development.
In preclinical studies, the total and functional antibody
titres as well as T-cell responses (IFN gamma secreting
CD4 and CD8 cells) induced by the vaccine are usually
measured prior to taking a candidate vaccine into clinical
trials. However, results obtained in rodents and occasion-
ally even in non-human primates are often not predictive
of the vaccine’s efficacy in humans. Even if a vaccine
proves effective, side-effects due to local and systemic
inﬂammatory reactions may lead to termination of its
development. Unfortunately, there is currently only a
limited set of biomarkers available to predict safety in
humans based on animal experimentation (e.g. pyroge-
nicity). There is thus a pressing need for the identiﬁcation
of biomarkers to guide the preclinical and clinical devel-
opment of vaccines. To this end, ‘systems biology’ – an
emerging discipline that employs bioinformatics to com-
putationally model molecular networks – is increasingly
being applied to study the complex immunological
responses to vaccination in order to deﬁne genetic signa-
tures of immune cells, which are predictive of efficacy and
safety of vaccines (Oberg et al., 2011). The term ‘systems
vaccinology’ has been coined for this approach
(Pulendran et al., 2010). This mini-review provides an
overview of recent results of the immunoproﬁling of
various vaccines in humans in vivo, aiming to identify
common gene signatures, which could be applied to
vaccine development. In addition, preliminary results from
our own proﬁling studies in non-human primates of a
number of licensed vaccines are presented.
Proﬁling of human immune responses
to vaccination
In the past few years gene expression proﬁling has been
utilized to capture a global view of the post-vaccine
immune response. PBMC or whole blood of humans
immunized with a number of different vaccines have been
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(YF17D) (Gaucher et al., 2008; Querec et al., 2009), live
attenuated measles vaccine (Haralambieva et al., 2010),
live attenuated Francisella tularensis vaccine (Fuller
et al., 2007), live attenuated tuberculosis vaccine (BCG)
(Fletcher et al., 2009), live attenuated and trivalent
subunit inﬂuenza vaccines (Zhu et al., 2010; Bucasas
et al., 2011), and a recombinant subunit malaria vaccine
(RTS,S) (Vahey et al., 2010). The latter study is particu-
larly interesting as vaccinees were subjected to challenge
with live parasites, permitting investigation of gene signa-
tures associated with vaccine efficacy. Similar pre- and
post-challenge expression proﬁling has been done in non-
human primates, as well. In one such study, rhesus
macaques were immunized with adenovirus-vectored HIV
vaccines and challenged with simian immunodeﬁciency
virus (Palermo et al., 2011). Salient features of these
studies will be discussed below.
Yellow fever
In the yellow fever vaccine (YF17D) studies, early post-
vaccination gene signatures predictive of CD8+ T cell
responses and neutralizing antibody responses were
identiﬁed with 90% and 100% accuracy respectively
(Querec et al., 2009) and transcription networks regulated
by STAT1, IRF7 and ETS2 were shown to be involved in
multi-functional and persistent immune responses
(Gaucher et al., 2008). Speciﬁcally, the gene encoding the
growth factor BAFF/BLyS (a TNF-like cytokine that sup-
ports survival and differentiation of B cells) was present in
all 15 gene signatures collected during two independent
Yellow fever 17D immunization trials and correlated with
the induction of neutralizing antibody responses. The key
genes in predictive signatures for CD8+ T cell responses
were SLC2A6, which encodes GLUT1, a membrane
protein regulating glucose transport and glycolysis, and
EIF2AK4, which is associated with stress response and
phosphorylation of the translation initiation factor eIF2a.
Other genes involved in the stress response were found
to be upregulated as well, prompting the hypothesis that
the induction of an integrated stress response in the
innate immune system might play a key role in shaping
the CD8+ T cell response to yellow fever vaccine
(Pulendran et al., 2010).
Measles
In a study comparing cytokine secretion patterns and gene
expression, PBMCs isolated from donors who had been
immunized against measles were stimulated with different
measlesvirusvaccineorwild-typestrains.Itwasfoundthat
the highly attenuated measles virus strain Edmonston tag
inducedTh1andTh2Tcellresponsesaswellasinnateand
inﬂammatory cytokine responses (Haralambieva et al.,
2010). In contrast, viruses expressing a functional wild-
type phosphoprotein (P) gene elicited predominantly
inﬂammatory cytokine responses, characterized by mod-
erate to low levels of IL-6 and IL-1b secretion, while sup-
pressing other cytokine responses including IFNs. These
data support previous ﬁndings that wild-type paramyxovi-
rus P, V, and C proteins inhibit IFNa/b induction and IFN
(a/borg)signallingbyinterferingwithdifferenttranscription
network regulators such as STATand JAK1, or by interact-
ing with MDA5 to block dsRNA binding.
Tularaemia
A study proﬁling immune responses to an intradermally
inoculated, live attenuated F. tularensis vaccine (LVS) in
adults revealed that the most pronounced changes in
PBMC gene expression occurred at early post-
vaccination time points ( 48 h), and most immune
related genes that were upregulated followed this pattern
(Fuller et al., 2007). Robust early upregulation of pro-
inﬂammatory and innate-immunity related genes, such as
IL-18, IL13-RA1, IRAK-3, CD39, CD116 and several TLRs
(notably 4 and 8), is indicative of functional responses
such as phagocytosis, exocytosis, super oxide formation,
antigen processing, cytokine/chemokine production, and
signal transduction. In aggregate, these data indicate a
strong activation of dendritic cells and other innate
immune system cells. However, the largest number of
immune related genes was found to be downregulated
early. This pattern suggests that numerous genes are
selectively up- or downregulated in a timeframe consis-
tent with innate effector activation, with resultant modiﬁ-
cation of the environment in which immune cell activation
will take place, and possibly dampening an overshooting
inﬂammatory response. Subsequent upregulation of
genes in the late post immunization period (8 and 14 days
p.i.) corresponded temporally to acquired immune effector
activation; however, of the late upregulated genes, only
one was immune-related – LCK (lymphocyte cell-speciﬁc
protein tyrosine kinase, involved in surface receptor sig-
nalling in NK, NKT and T-cells). Most genes upregulated
at the late time point have biosynthetic and metabolic
functions, which is consistent with upregulation of a coor-
dinated immune response. Nine of 42 genes with a
pattern of sustained upregulation throughout the 14 days
of the study were directly linked to immune function.
Among these were genes associated with innate defence
mechanisms such as regulators of endocytosis/
phagocytosis, granule exocytosis, chemotaxis and inﬂam-
matory cytokines. Intradermal injection of LVS results in
formation of a pustule, clearly visible by 18 h p.i., which
eventually ulcerates. While the humoral response to LVS,
as measured by microagglutination assay, was highly
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revealed that the vaccine elicited a consistent response
across all genes and at all time points in all vaccinees
(correlation > 0.88).
Tuberculosis
Live attenuated mycobacterium tuberculosis vaccine
(BCG), which is given intradermally at birth, was immuno-
proﬁled in PBMC isolated from ﬁve infants 10 weeks post
immunization. Interestingly, puriﬁed protein derivative of
tuberculin (PPD) and live BCG induced similar gene
expression proﬁles in isolated PBMC characterized by
upregulation of genes associated with the classic, pro-
inﬂammatory macrophage response (IL-6, GM-CSF,
IL1F9) and downregulation of leucocyte genes. In general,
a larger number of genes was found to be downregulated
rather than upregulated. Notable among the downregu-
lated genes were genes of the peroxisome proliferator-
activated receptor (PPAR) signalling pathway, which is
involved in activation of the alternative, anti-inﬂammatory
macrophage response. Thus, a particular combination of
suppressed and upregulated genes may be key in deter-
mining immunity to TB (Fletcher et al., 2009).
Inﬂuenza
Several studies have proﬁled the immune responses to
trivalent inactivated inﬂuenza vaccine (TIV) and to live
attenuated trivalent vaccine (LAIV). Two distinct temporal
patterns of gene expression in response to immunization
withTIV were observed in 92 adults (Bucasas et al., 2011).
The early phase of transcriptional activation (24 h post
immunization) was characterized by upregulation of genes
whoseproductsactonhostviralsensingthroughTLR7and
TLR8, resulting in signiﬁcantly increased transcript levels
of genes participating in the antiviral defence response,
cellular activation and differentiation (e.g. IFN response
pathway, JAK/STAT signal transducers, NF-kB). In con-
trast,thelateresponse(2weeksp.i.)wascharacterizedby
upregulation of genes involved in cellular proliferation.The
abundancelevelsof494transcriptscorrelatedsigniﬁcantly
with the haemagglutination titre response index. Interest-
ingly, the difference between expression of the genes
STAT1 and E2F2 alone generated a gradient that corre-
sponded clearly to the titre response index at the two
extremes of the response spectrum. Thus, early upregula-
tion of interferon and antigen presentation pathways are
associated with a higher antibody response. In contrast,
the majority of upregulated genes and enriched functional
pathwaysinlowresponderswerenotspeciﬁcallyrelatedto
cell-mediated immune responses.
In another study the immunogenicity and regulation of
recall responses was evaluated by a series of clinical
studies performed during the annual inﬂuenza seasons in
three consecutive years, in which a total of 56 young
adults were immunized either with TIV or LAIV (Nakaya
et al.,2011).ProﬁlingwasdoneinPBMCandFACSsorted
subsets of immune cells. In addition, cell type-speciﬁc
transcriptional signatures were discerned in the PBMC
microarray analyses, based on a meta-analysis of publicly
available microarray studies in which the gene-expression
proﬁles of isolated individual cell types of PBMCs (T-,
B-cells, monocytes, NK cells, etc.) had been analysed.
Antibody responses to vaccination (HAI titres) were much
higher in TIV than LAIV recipients. In subjects vaccinated
with TIV, myeloid DCs and B cells had the most differen-
tially expressed genes (DEGs), whereas in subjects vac-
cinated with LAIV plasmacytoid DCs had the most DEGs.
The molecular signature induced by vaccination with LAIV
was characterized by genes encoding molecules closely
associated with the interferon signalling pathways, such
as STAT1, STAT2, TLR7, IRF3 and IRF, with the greatest
difference in gene expression observed at day 3 post
immunization. Cell-type speciﬁc analysis showed high
expression of most interferon-related genes in monocytes
and natural killer cells. In contrast, the signature induced
by vaccination with TIV was characterized by upregulation
of genes encoding two transcription factors, XBP-1 and
ATF6B, which are central to regulating the unfolded
protein response. This was detectable in sorted antibody
secreting cells, consistent with the requirement of these
cells to enhance their capacity to secrete large amounts of
correctly folded immunoglobulins. Interestingly, genes
with high expression included TNFRSF17 (encoding
BCMA, a member of the BAFF-BLyS family of receptors),
whose expression has been shown before to be a key
feature of the best predictive signatures of neutralizing
antibody responses to YF-17D (Querec et al., 2009). In
total, 42 sets of gene signatures (3–4 genes each) were
identiﬁed by discriminant analysis via mixed integer pro-
gramming (DAMIP) to predict ‘high’ or ‘low’ responders to
TIV vaccination (> fourfold HAI titre increase) with an esti-
mate of correct classiﬁcation > 85%.To test the hypothesis
that this approach can identify novel mechanisms of
immune regulation, the authors investigated the role of the
gene CaMK4, whose expression was negatively corre-
lated with HAI titres on day 28. CaMKIV is known to be
involved in T cell development, inﬂammatory responses
and the maintenance of haematopoietic stem cells, but its
role in B-cell responses is not known. In vitro stimulation of
mouse and human splenocytes with TIV resulted in phos-
phorylation of CaMKIV, suggesting that the vaccine may
trigger activation of CaMKIV, and immunization of wild-
type and CaMK-/- mice resulted in threefold to 6.5-fold
higher antibody titres in the knock-out mice (Nakaya et al.,
2011). These results suggest that CaMKIV is important in
the regulation of the B cell response.
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To date, two studies have reported immunoproﬁling that
identiﬁed gene signatures or signalling pathways, which
were correlated with vaccine efficacy against experimen-
tal challenge. In one study, volunteers receiving three
doses of adjuvanted RTS,S vaccine (Plasmodium falci-
parum circumsporozoite sequences fused to the hepatitis
B surface antigen) were challenged by the bites of
infected mosquitoes. Genes associated with host inﬂam-
matory response, apoptosis, and the protein kinase
cascade were upregulated within 24 h of the third vacci-
nation, regardless of the outcome after challenge.
However, gene set enrichment analysis performed on
samples obtained 2 weeks after the third vaccination
revealed that upregulation of genes in the proteasome
degradation pathway (PSME2, PSMB9, PSMB6, PSMA4)
was associated with protection (Vahey et al., 2010).
These genes play complex roles in the efficiency of MHC
peptide processing and antigen presentation.
HIV
In an AIDS vaccine trial in rhesus macaques, the animals
were primed twice (orally plus intranasally, followed by
intratracheally) with a replication competent adenovirus 5
vector, which expressed human immunodeﬁciency virus
(HIV) envelope protein, simian immunodeﬁciency virus
(SIV) gag protein or SIV nef protein, alone or in combina-
tion with two intramuscular boosts with recombinant HIV
gp140 protein or an HIV peptomer in monophosphoryl
lipidAstable solution (Palermo et al., 2011).Animals were
challenged intravenously with a SHIV89.6P challenge stock,
and peak viral load and time to viral set point were mea-
sured. While at peak viraemia the expression proﬁles of
the immunized animals were very similar, the best-
protected animals showed upregulation of genes related
to B-cell development and lymphocyte survival pre-
challenge; increased expression of IL-27 and complement
components post-challenge were identiﬁed as possible
mechanisms of protection. Divergent expression proﬁles
at the viral set point for the different immunized groups
implied distinct immunological responses despite pheno-
typic similarities in viral load and CD4+ T-cell levels.
Head-to-head comparison of vaccine-induced gene
signatures in the blood of non-human primates
A whole-blood gene expression database comparing the
response of non-human primates to a panel of marketed
(Adacel, Menactra, Havrix, Prevnar and RabAvert) and
experimental vaccines are shown in Fig. 1. Among the
experimental vaccines, V512 is an inﬂuenza vaccine
based on the ectodomain of the M2 protein conjugated to
Outer Membrane Vesicles of Neisseria meningitidis sero-
type B11; MRKAd5-gag is an HIV vaccine based on a
Fig. 1. Overall blood gene signatures in non-human primate immunized with seven marketed or experimental vaccines. Genome-wise gene
expression data were collected from 8 time points including 0 h (baseline), 4 h, 8 h, 24 h, 1 week, 2 weeks, 3 weeks and 4 weeks post
vaccination. For each vaccine formulation, a one-way ANOVA was performed to select for signature genes modulated at any one of 7 time
points post vaccination in comparison to the baseline at P  0.001. The heatmap shows expression values in Log(Ratio) of 23 653 sequences
derived from the union of 10 ANOVA gene lists. The signatures are robust and both common and unique signature clusters can be identiﬁed
among tested vaccines. For examples, genes in clusters 6, 10 and 11 are generally upregulated in all tested vaccines at day 1 (i.e. 4, 8 and
24 h post vaccination) although the intensities are variable among vaccines; genes in clusters 9 and 14 are upregulated at later time points
(weeks 2–4) whereas genes in clusters 2 and 13 are generally downregulated. There are also vaccine-speciﬁc gene signatures such as
cluster 4, which is speciﬁcally upregulated by Menactra and cluster 1, which is predominantly upregulated by MRKAd5 and Havrix.
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gag. Genome-wide gene expression data for each
vaccine were generated from 4 rhesus monkeys at 8
separate time points (pre-vaccinated baseline, post-
vaccination at 4, 8, 24 h, and days 7, 14, 21 and 28).
One-way ANOVA analysis was performed individually for
each vaccine and used to generate a heat map for the
union of 10 ANOVA-derived signatures (Fig. 1). In addition,
the blood module approach (Chaussabel et al., 2008) and
the metagene model (Huang et al., 2003) for identifying
gene signatures were employed to obtain gene signa-
tures. Annotation was performed using pathway analysis
tools such as Ingenuity (Ganter and Giroux, 2008).
In general, all vaccines induced robust blood gene sig-
natures at the ANOVA P-value selected (> 20 000
sequences in Fig. 1) with clear time-dependent kinetics.
Each vaccine generated a unique gene expression
pattern across time points although some relatively
common features can be detected. For example, clusters
6, 10 and 11 (Fig. 1) contain genes associated with innate
immunity, cytokine production and responses to virus
infection, including IFN-inducible genes. These genes
were upregulated by all vaccines at early time points and
decreased thereafter; similar gene sets were induced by
yellow fever and inﬂuenza vaccines as reported previ-
ously (Gaucher et al., 2008; Querec et al., 2009 and
Bucasas et al., 2011). The extent of upregulation induced
by the experimental vaccines (i.e. V512/inﬂuenza and
MRKAd5-gag) was generally higher than by the marketed
vaccines. Clusters 9 and 14 include genes whose expres-
sion was downregulated at early time points but was
increased after one week. These genes are linked to T cell
receptor signalling, cell cycle progression, and response
to stress. Gene clusters predominantly modulated by
certain vaccines were also observed; for example, clus-
ters 1 and 7, which are induced mainly by the MRKAd5-
gag vaccine and to lesser extents by the V512/inﬂuenza
and Havrix vaccines, point to genes associated with the
ubiquitin pathway, protein folding and mitochondrial dys-
function. Clear vaccine dose-dependent expression pat-
terns and adjuvant-induced signatures were found with
the three different doses of MRKAd5-gag vaccine and
V512 inﬂuenza vaccine with or without ISCOMATRIXTM
respectively (Fig. 1).
More detailed pathway engagement information was
acquired when each vaccine was examined separately.
For instance, at early time points, Adacel administration
activates key innate immunity-related pathways including
Toll-like receptor (TLR), GM-CSF and FcgR signalling and
downregulates adaptive immunity-related pathways
including T cell receptor, NK cell, and CCR5 signalling.
The expression patterns of these innate immunity-related
versus adaptive immunity-related signalling pathway
genes reverse between early (4–24 h post vaccination)
and later time points (1–2 weeks post vaccination), which
is consistent with the general vaccine-induced gene
expression patterns shown in Fig. 1. This type of analysis
may provide a framework for hypothesizing how a particu-
lar vaccine works to exert its protective activity.
We also identiﬁed pre-deﬁned gene modules as well as
de novo gene clusters, which are correlated to a com-
bined adverse event scores derived from human clinical
data (manuscript in preparation). In another internal pre-
clinical study, we identiﬁed another set of gene modules
and signatures, which are either positively or negatively
correlated to antibody titres from monkeys vaccinated
with an experimental vaccine formulated with a panel of
test adjuvants. We observed a consistent result with a
recently published article of Nakaya and colleagues
(2011), who showed that T cell receptor signalling genes
are negatively correlated to TIV Ab titres in humans.
Conclusion and outlook
Results emerging from proﬁling of immune responses to
vaccination suggest that the type and duration of immune
memory are largely determined by the magnitude and
complexity of the innate immune signals that prime the
acquired immune responses. As evident from the in vivo
proﬁling studies, the extent of upregulation of immune-
related and especially interferon regulated genes is gen-
erally higher following administration of live attenuated
vaccines than inactivated vaccines. However, early
upregulation of pro-inﬂammatory and innate immune
genes seems to be off-set by concomitant or subsequent
downregulation of several immune related genes, possi-
bly to dampen overshooting inﬂammatory reactions.
Some general principles of successful priming of the
innate immune system are evident from vaccination
studies performed in humans, and in several cases the
same ‘genetic master switches’ of antigen processing and
presentation, as well as B-cell and T-cell activation, have
been found (Table 1); however, gene signatures predic-
tive of speciﬁc adaptive immune responses vary widely in
these studies, as would be expected from the variety of
vaccine compositions, adjuvants and routes of inoculation
used in these studies, not to mention variation introduced
by the different methodologies used to analyse the data.
An important question is therefore whether common
genetic signatures can be identiﬁed that will predict immu-
nogenicity of different vaccines. To this end the recent
comparison of inactivated trivalent inﬂuenza vaccine (TIV)
to live attenuated Yellow fever 17D vaccine (YF-17D) is
very interesting. For both vaccines high expression of
TNFRSF17, which encodes BCMA, was found to be part
of gene signatures predicting the development of high
titres of functional antibodies (Querec et al., 2009;
Nakaya et al., 2011).
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BAFF-R and TACI) that regulate the differentiation of
plasma cells and antibody production. Notably, there were
strong correlations between the expression of these
genes and the magnitude of the HAI titres in response to
vaccines against inﬂuenza and the magnitude of neutral-
izing antibody response to YF-17, which suggests that this
network may be critically involved in regulating antibody
responses to different vaccines (Nakaya et al., 2011).
Thus, transcriptional proﬁling may provide an avenue
towards identifying potential novel immune mechanisms
that could be integrated into vaccine and adjuvant discov-
ery and development (reviewed by Pulendran et al., 2010;
Buonaguro and Pulendran, 2011).
Only a few human challenge models for infectious dis-
eases exist, and thus far, genetic biomarkers predictive of
vaccine efficacy have been described only for a recombi-
nant malaria vaccine. In general, the value of vaccine
immunoproﬁling studies would be enhanced if more
human challenge models for infectious diseases were
developed.
Blood immune transcriptome analysis will also help
answer two very important questions: why are the elderly
less likely to develop protective immune responses after
vaccination and why are there differences among indi-
viduals in terms of susceptibility to a particular infectious
pathogen? To this end, the National Institute ofAllergy and
Infectious Diseases (NIAID) recently launched a ‘Human
Immune Phenotyping Initiative’, a $100-million program to
be carried out at six institutes across the USA to facilitate
research that employs this immune ‘ﬁngerprints’ approach
to understand vaccines and infectious diseases. It can be
anticipated that due to the increased availability of gene
arrays and next-generation sequencing an increasing
amount of genetic data linked to vaccine immunogenicity,
safety and in some cases efficacy in humans will become
available (Dhiman et al., 2009). It will, however, remain a
challenge to identify true causal relationships between the
genetic signature(s) induced by a speciﬁc vaccine and
their observed biological correlates (Pulendran et al.,
2010). In addition, comparison of genetic biomarkers pre-
dictive of safety and efficacy across different vaccines
would beneﬁt from some standardization of the method-
ologies applied to proﬁling and computational analysis.
With a few exceptions (e.g. BCMA), the set of affected
genes (even for similar vaccine preparations, such as ﬂu)
seems to be rather large, heterogeneous and diverse,
which currently limits their practical use as biomarkers.
Furthermore, the comparability of studies is limited due to
the variety of methods employed for detection and com-
putation of gene expression differences and genetic sig-
natures (Table 1); ultimate proof of the importance of
certain genes may require their knock-out in animal
models (Nakaya et al., 2011).
Nonetheless, these early studies of transcriptional pro-
ﬁling have provided remarkable insight into the vast
panoply of genes involved in immune responses stimu-
lated by vaccination. The challenge of the future is clear:
how do we tease out of these data-speciﬁc markers that
will predict safety and efficacy of vaccine candidates in
development, thereby reducing the risks and costs of
vaccine development.
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